Stratified glucocorticoid monotherapy is safe and effective for most cases of giant cell arteritis by Karabayas, Maira et al.
Concise report
Stratified glucocorticoid monotherapy is safe and
effective for most cases of giant cell arteritis
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Abstract
Objectives. High-dose glucocorticoids anchor standard care in GCA but are associated with significant
toxicity. We aimed to evaluate the safety and effectiveness of a stratified approach to glucocorticoid
tapering. The strategy aggressively reduced glucocorticoid doses in those manifesting an adequate early
response to treatment, with a view to minimizing glucocorticoid complications.
Methods. A retrospective, population-based study of GCA was performed. All cases were confirmed
by temporal artery biopsy between November 2010 and November 2015. Baseline and outcome data
were extracted from secondary and primary care records at diagnosis and 1 year follow-up. The pri-
mary outcome was loss of vision. Secondary outcomes included remission and relapse rates and CS-
related complications.
Results. The cohort consisted of 73 patients (76% female; mean age 73.5 years, S.D. 7.6 years).
At presentation, a reduction in visual acuity was recorded in 17 patients (22.3%). The median CRP at
diagnosis was 69.5 mg/l [interquartile range (IQR) 40.5–101 mg/l], with a median ESR of 80 mm/h (IQR
60–91 mm/h). At 1 year, remission was achieved in 64 patients (87.7%), whereas 10 patients (13.7%)
relapsed. A single patient sustained visual loss after initiation of therapy. The median CRP at 1 year
was 4 mg/l (IQR 4–9.5 mg/l) and the mean prednisolone dose was 5.4 mg (0–15 mg). CS-related compli-
cations were observed in 10 patients (13.7%).
Conclusion. A stratified approach to CS tapering appeared safe and effective in GCA. It was associated
with a high rate of remission and promisingly low rates of relapse at 1 year follow-up. These real-world
data indicate that glucocorticoid exposure can be minimized safely in some patients with GCA.
Key words: giant cell arteritis, temporal artery biopsy, retrospective cohort, glucocorticoid, tapering regi-
mens, visual loss, remission, relapse
Introduction
GCA is the commonest form of vasculitis in Caucasians.
It has a predilection for the cranial arteries, with patients
classically presenting with temporal headache, a spec-
trum of visual disturbance, jaw claudication and a de-
gree of constitutional upset [1].
Key messages
. A stratified approach to glucocorticoid tapering is effective for most cases of GCA.
. Glucocorticoid exposure can be aggressively, yet safely minimized in selected patients with GCA.
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The most catastrophic complication of the disease is
loss of vision related to myo-intimal proliferation and
subsequent vessel occlusion. This is typically unilateral
but can be observed bilaterally and is often permanent.
In historical cohorts, before the introduction of glucocor-
ticoid (GC) therapy, visual complications were estimated
in 35–60% of patients [1]. However, more recent studies
suggest that visual loss occurs in 13.2–19.1% of GC-
treated patients [2–4]. Although the risk of visual loss
reduces significantly once CS therapy is initiated, in clin-
ical practice the fear of inadequate therapy in relation-
ship to this complication might encourage excessive CS
use [5].
Historically, GCs have been the mainstay of treatment.
A recent review identified a number of CS regimens, al-
though these have not yet been validated, and variability
in CS protocols in clinical practice remains an issue [6].
Moreover, GC toxicity is an increasing concern, with
data attributing a significant proportion of morbidity to
their adverse effects [7]. A GCA cohort analysis showed
a significant risk of adverse rates for every 1 g increase
in the cumulative GC dose (odds ratio 1.17, 95% CI:
1.06, 1.29) [8].
Research initiatives are directed towards management
strategies to reduce the overall burden of GCs, without
enhancing the risk of visual compromise [9]. Evidence
now supports an effective GC-sparing role for modern
biologics, although high financial cost limits their acces-
sibility [10–12]. In other forms of vasculitis, there are
now data indicating that historical management proto-
cols incorporate dispensable doses of GC. Aggressive
tapering regimens appear to be equivalently effective
but with preferable safety profiles. Similar evidence is
lacking for GCA and was advocated as a research prior-
ity in the 2009 EULAR large vessel vasculitis manage-
ment recommendations [9].
Since 2010, our centre has taken an aggressive
approach to GC tapering, with the aim of minimizing
treatment-related complications. However, in order to mini-
mize the risk of visual compromise, patients slow to re-
spond are stratified to receive a classical tapering regimen
(Fig. 1). We have now conducted a retrospective study
to examine the performance of this new GC strategy.
Methods
We conducted a retrospective observational study on a
population-based cohort of GCA in the North East of
Scotland. Patients >50 years of age with a positive tem-
poral artery biopsy, as reported by the local pathology
department, were included. No ethical approvals were
required. The project was registered with the local
Research and Development department.
All temporal artery biopsies carried out between
November 2010 and November 2015 in the Grampian
region of Scotland (population 550 000) were identified
from a centralized pathology database. Electronic
primary and secondary care records were interrogated
to extract patient demographics and disease
characteristics at the time of diagnosis and outcomes at
1 year follow-up. Individual primary care practices were
contacted to determine an accurate prednisolone dose
at 1 year for each patient. Patient demographics in-
cluded age, sex and smoking status. Baseline disease
characteristics assessed included headache, visual dis-
turbance, jaw claudication, constitutional upset and in-
flammatory markers at diagnosis. The primary outcome
examined was loss of vision (defined as complete mon-
ocular visual loss) at 1 year. Secondary outcomes in-
cluded the rate of remission (defined as prednisolone
dose 7.5 mg and complete resolution of symptoms),
rate of relapse (defined as recurrence of symptoms re-
quiring escalation of any immunosuppression) and CS-
related complications at 1 year.
In our region, all patients with suspected GCA are im-
mediately started on prednisolone 60 mg in primary care
and then fast-tracked to a central neuro-ophthalmology
clinic. They are reviewed and clinically assessed within
2 days. Temporal artery biopsy is undertaken at most
within 2 weeks of diagnosis. All patients then follow the
stratified CS taper illustrated in Fig. 1. Patients are re-
assessed between weeks 3 and 6 to determine ade-
quate response (defined as complete resolution of
symptoms and CRP <10 mg/l). When clinically appropri-
ate, patients are discharged from the specialist clinic
back to primary care with the recommended CS taper
as outlined above. All patients remain on 5 mg until the
anniversary of diagnosis. They reduce further by 1 mg
monthly until CS cessation. In the event of any clinical
concerns within primary care, patients are usually re-
referred to the neuro-ophthalmology clinic.
The study was a clinical service evaluation and com-
plied with local institutional governance.
Results
During the 5 year study period, a total of 329 temporal
artery biopsies were performed. Of those, 246 were non-
diagnostic and 83 were positive for GCA. Of the 83 positive
cases, complete outcome data were available for 73.
Our final cohort consisted of 73 patients, 76% of
whom were female, with a mean age at diagnosis of
73.5 (S.D. 7.6) years. At the time of diagnosis, objective
monocular reduction in visual acuity relating to GCA
was recorded in 17 patients (22.3%). More specifically,
11 patients presented with anterior ischaemic optic neu-
ropathy, 3 with central retinal artery occlusion, 2 with
sixth nerve palsy and 1 with posterior ischaemic optic
neuropathy. However, 39 patients (53.4%) reported sub-
jective visual disturbances ranging from undifferentiated
visual impairment (n¼20) to blurry vision (n¼ 10) and
diplopia (n¼ 8). Jaw claudication was reported in 34
patients (46.6%) in the cohort, and 37 (50.7%) described
a degree of constitutional upset. On examination, 20
(38.4%) reported temporal artery tenderness. All patients
fulfilled ACR criteria 1990 [13]. At the time of diagnosis,
the median CRP was 69.5 mg/l [interquartile range (IQR)
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40.5–101 mg/l] and the median ESR was 80 mm/h (IQR
60–91 mm/h) (Table 1).
At 1 year, remission was achieved in 64 patients
(87.7%) of the cohort, whereas 10 (13.7%) relapsed.
The reported relapses were mainly in the form of head-
ache and constitutional upset requiring temporary esca-
lation in prednisolone dose. A single patient sustained
visual loss from initiation of therapy. The median CRP at
1 year was 4 mg/l (IQR 4–9.5 mg/l), with a mean prednis-
olone dose of 5.4 mg (0–15 mg), and two patients re-
quired additional immunosuppression. The mean
discharge time from neuro-ophthalmology clinic was
18.3 weeks (S.D. 17 weeks). CS-related complications
were observed in 15 patients (20.6%), cataract in 4, re-
current urinary tract infections n¼ 3, thoracic wedge
fracture n¼ 2, avascular necrosis of femoral head n¼ 1,
pelvic fracture in 1, CS-induced diabetes in 1, CS-
induced psychosis in 1, intra-abdominal sepsis requiring
hospital admission in 1 and osteoporosis in 1. Finally,
the estimated cumulative prednisolone dose for the ag-
gressive CS taper (group 1) was 2997.5 mg, and the es-
timated cumulative dose for the slower group was
4385mg. It was not possible to evaluate differences in
outcomes between CS regimens.
Discussion
In this single-centre observational retrospective study of
a service which adopts an aggressive GC minimization
taper in early GC responders, visual loss was rare
(1.4%), despite patients tapering to 20 mg of predniso-
lone by 4 weeks. The majority of patients achieved dis-
ease remission (87.7%), and relapse was uncommon
(13.7%).
Our low observed rates of visual loss align with those
reported from another population-based cohort.
Salvarani et al. [14] examined visual manifestations in
Italian patients with biopsy-proven GCA (n¼ 136). They
reported a single patient sustaining permanent visual
loss 14 months from the initiation of treatment. Aiello
et al.[2] found a 1% 5 year probability of developing new
visual loss from initiation of therapy in an era where GC
dosing was significantly higher.
TABLE 1 Patient demographics and baseline disease
characteristics
Characteristic Value
Age, mean (S.D.), years 73.5 (7.6)
Female, n (%) 56 (76)
ACR criteria 1990 fulfilled, n (%) 73 (100)
Headache, n (%) 65 (89)
Jaw claudication, n (%) 34 (46.6)
Constitutional upset, n (%) 37 (50.7)
Subjective visual impairment, n (%) 39 (53.4)
Objective reduction in
visual acuity, n (%)
17 (22.3)
Temporal artery tenderness, n (%) 20 (38.4)
CRP, median (interquartile range), mg/l 69.5 (40.5–101)
ESR, median (interquartile range), mm/h 80 (60–91)
Fig. 1 CS tapering protocol
Stratified glucocorticoid tapering in GCA
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Disease remission was achieved by 87.7% of the co-
hort. In general, existing literature indicates that only 15–
20% of patients achieve this disease state with GC
monotherapy [10]. Furthermore, our promisingly low
rates of relapse (13.7%) also appear favourable in com-
parison to the extant literature, where typically rates be-
tween 34 and 74.5% have been reported [15, 16]. There
are a few reasons for these discrepancies. First, remis-
sion and relapse rates vary significantly within clinical tri-
als and population-based cohort studies. These figures
should be interpreted cautiously given the difficulty of
adjusting for confounding factors such as disease dura-
tion, cumulative CS use and follow-up time. Second,
there are significant variations in the definitions used for
remission and relapse, which have only been standard-
ized recently in the updated EULAR recommendations
[12]. It is hoped that future studies will assess these
newly homogenized outcomes in a more systematic
manner to inform clinical practice. Third, our cohort con-
sisted of patients presenting with cranial symptoms. It
has been shown that cranial GCA is usually associated
with a more monophasic disease course [17]. That said,
we did not routinely perform specialist imaging to con-
firm the presence or absence of extracranial artery in-
volvement. Fourth, the majority of the literature is
sourced from specialized centre sampling frames. More
recent population-level real-world data provide evidence
for low relapse rates [18]. Although these data align with
our observations, it should be noted that this was a con-
ference abstract publication, with inherent limitations
and potential methodical flaws and has not been peer
reviewed. Finally, we speculate that our fast-track ser-
vice has enabled very early diagnosis, which allowed for
the application of a stratified approach to GC tapering,
in turn conferring favourable long-term outcomes.
Prognostic benefits of early therapy are certainly now
established across other rheumatic disorders [19].
Adverse events relating to GC therapy at 1 year were
prevalent. The estimated cumulative prednisolone dose
for the aggressive CS taper (group 1) was 2997.5 mg, a
value which compares directly with the 26 week CS pla-
cebo group (3296 mg) and significantly less than the
56 week steroid placebo group, in the GiACTA trial
(3818 mg) and the group 2 CS taper (4385 mg), which
mirrors classical regimens [11]. It is important to high-
light that the values related to our cohort assume full
compliance with the taper protocol. Owing to difficulties
with data capturing, we were not able to confirm this
retrospectively for each individual patient to provide an
accurate mean cumulative dose.
Several other limitations should also be considered.
Firstly, this study is retrospective in design and depen-
dent on electronic records for data extraction. In our re-
gion, however, electronic records are centralized,
including laboratory, clinical and pathology records. In
addition, a direct link between primary and secondary
care made it feasible to capture a wide range of data.
Incomplete data capture remained a challenge; for ex-
ample, it was not possible to characterize group
assignment confidently. The mean discharge time from
the ophthalmology clinic to primary care was 18.3 weeks
(S.D. 17 weeks) from the time of diagnosis. Adherence to
the standardized CS taper was assumed in the absence
of any referrals back to ophthalmology or rheumatology
clinics or any relapses documented in primary care
records. To account for that, we also contacted individ-
ual practices to obtain an accurate personalized pred-
nisolone dose at 1 year for all patients. Secondly,
outcomes were examined only at 1 year, and it is possi-
ble that we might have failed to capture later relapses.
A longitudinal study cohort showed a mean time to first
relapse of 79 (S.D. 75) weeks [range 11–339 weeks, me-
dian 51 (IQR, 89) weeks], but 50% of these patients re-
lapsed within the first year [20].
Thirdly, in order to ensure that our cohort consisted of
patients with a true diagnosis of GCA, we elected to
include only those with a positive temporal artery
biopsy. Owing to the lack of sensitivity of temporal ar-
tery biopsy, we might have missed cases. Our patient
demographics align with epidemiological predictions
predominantly affecting women (3.3:1), with a mean age
at diagnosis of 73.5 (S.D. 7.6) years [21]. A retrospective
analysis examining the incidence of GCA in the UK
between 1990 and 2001 suggested that the age-
standardized incidence ratio of GCA in Scotland is 67
(95% CI: 54, 82), a figure which directly compares to
our cohort [22]. Taken together, we are likely to have
captured a representative cohort. What transpires from
this retrospective study is that having a centralized, fast-
track service allows the application of an aggressive,
stratified CS taper to reduce cumulative CS burden,
whilst ensuring that patient outcomes are optimal.
Although our study demonstrates reassuring out-
comes, these findings are preliminary. Adoption of this
stratified CS taper in different populations would be
required to validate these observations further and
correct for some of the limitations discussed. A larger
prospective longitudinal study is desirable to quantify
GC exposure more precisely and to characterize further
the morbidity relating to both disease and treatment.
This would make it possible to differentiate and pheno-
typically characterize the two CS taper groups, in an at-
tempt to inform our future practice as the field finally
moves towards to an era of personalized medicine.
Conclusions
In conclusion, in this retrospective observational study
of a real-world population cohort in the North East of
Scotland, a stratified approach to corticosteroid therapy,
which leveraged initial treatment response as a method
to triage patients towards aggressive steroid tapering,
appears to be an effective model of the GCA pathway.
It was associated with high rates of remission and
promisingly low rates of relapse at 1 year follow-up.
These real-world data suggest that glucocorticoid expo-
sure could safely be reduced compared with classical
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regimens when integrated in fast-track pathways with
early specialist input.
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